Rubedo Life Sciences
Rubedo Life Sciences is a clinical stage biotech company dedicated to discovering and developing medicines to keep individuals biologically young by targeting the cells that drive aging and diseases. Founded by leading scientists and entrepreneurs, the company aims to extend human health span through innovative research in aging, regenerative medicine, and drug discovery, leveraging artificial intelligence and informatics.
Industries
Nr. of Employees
small (1-50)
Rubedo Life Sciences
1234 Innovation Drive, San Francisco, CA 94107
Patents
Products
Clinical-stage senescence-targeted small-molecule candidate (topical formulation)
A clinical-stage small-molecule modulator targeting senescent-cell biology, progressed to first-in-human topical dosing in Phase I to assess safety and preliminary clinical effects in dermatologic and inflammatory indications.
Multi-omics discovery and senescent-cell phenotyping platform
An internal platform combining multi-omics assays and computational analysis to identify and phenotype senescent cell populations across tissues, supporting target selection and screening workflows; platform outputs supported by peer-reviewed publications.
Preclinical senolytic prodrug candidate (proof-of-concept)
A preclinical senolytic prodrug asset that demonstrated reversal of frailty and cognitive deficits in aged mouse models, serving as translational proof-of-concept for targeting senescent cells.
Preclinical pulmonary fibrosis program targeting senescent lung cells
A preclinical program focused on targeting senescent lung and progenitor cells for treatment of pulmonary fibrosis, developed in collaboration with academic medical centers and supported by translational research awards.
Clinical-stage senescence-targeted small-molecule candidate (topical formulation)
A clinical-stage small-molecule modulator targeting senescent-cell biology, progressed to first-in-human topical dosing in Phase I to assess safety and preliminary clinical effects in dermatologic and inflammatory indications.
Multi-omics discovery and senescent-cell phenotyping platform
An internal platform combining multi-omics assays and computational analysis to identify and phenotype senescent cell populations across tissues, supporting target selection and screening workflows; platform outputs supported by peer-reviewed publications.
Preclinical senolytic prodrug candidate (proof-of-concept)
A preclinical senolytic prodrug asset that demonstrated reversal of frailty and cognitive deficits in aged mouse models, serving as translational proof-of-concept for targeting senescent cells.
Preclinical pulmonary fibrosis program targeting senescent lung cells
A preclinical program focused on targeting senescent lung and progenitor cells for treatment of pulmonary fibrosis, developed in collaboration with academic medical centers and supported by translational research awards.
Services
End-to-end programs from target discovery and validation through translational modeling, formulation, IND-enabling activities and early clinical development.
Protocol design, trial initiation and execution support for first-in-human and early-phase studies, including safety monitoring, regulatory filing assistance and access to dermatology/oncodermatology investigator networks.
Development and operation of distributed data infrastructures, large-scale analysis pipelines, and chemistry-focused machine learning tools to accelerate discovery.
Strategic co-development and licensing arrangements with consumer and personal-care partners to translate therapeutic discovery into skincare and cosmeceutical products.
On-site, mentored internship projects providing hands-on training in translational research and regenerative-medicine techniques.
End-to-end programs from target discovery and validation through translational modeling, formulation, IND-enabling activities and early clinical development.
Protocol design, trial initiation and execution support for first-in-human and early-phase studies, including safety monitoring, regulatory filing assistance and access to dermatology/oncodermatology investigator networks.
Development and operation of distributed data infrastructures, large-scale analysis pipelines, and chemistry-focused machine learning tools to accelerate discovery.
Strategic co-development and licensing arrangements with consumer and personal-care partners to translate therapeutic discovery into skincare and cosmeceutical products.
On-site, mentored internship projects providing hands-on training in translational research and regenerative-medicine techniques.
Expertise Areas
- Senescence-targeted small-molecule therapeutics
- Medicinal chemistry and prodrug design
- Multi-omics target discovery and bioinformatics
- In vivo translational pharmacology and humanized disease models
Key Technologies
- Prodrug design and optimization
- Small-molecule medicinal chemistry and solid-phase combinatorial chemistry
- GPX4 pathway modulation
- Next-generation sequencing and transcriptomics
News & Updates
Rubedo announced the dosing of the first patient with its lead drug candidate RLS-1496, a GPX4 modulator targeting senescent cells, entering Phase 1 clinical trial.
A study utilizing Rubedo's ALEMBIC platform identified senescent neurons linked to neuropathic pain and aging, published in Nature Neuroscience.
The company disclosed its plans for clinical development of RLS-1496, a novel drug targeting aging cells.
Frederick Beddingfield III, an experienced biotech executive, has been appointed as CEO of Rubedo Life Sciences.
A partnership to develop skin care products targeting cellular aging.
Rubedo announced the dosing of the first patient with its lead drug candidate RLS-1496, a GPX4 modulator targeting senescent cells, entering Phase 1 clinical trial.
A study utilizing Rubedo's ALEMBIC platform identified senescent neurons linked to neuropathic pain and aging, published in Nature Neuroscience.
The company disclosed its plans for clinical development of RLS-1496, a novel drug targeting aging cells.
Frederick Beddingfield III, an experienced biotech executive, has been appointed as CEO of Rubedo Life Sciences.
A partnership to develop skin care products targeting cellular aging.